ABSRTACT

INTRODUCTION. Currently, in the scientific literature, the problem of the relationship between pain in the lower back and diabetes mellitus is given great attention, and therefore the term diabetic dorsopathy has appeared. 

CONCLUSION. The treatment strategy for a patient with back pain depends on the age of presentation, the severity of disc degeneration associated with nerve compression, the stability of the functional spine, and the overall balance of the spinal column (ie, sagittal balance). Therapy for diabetic dorsopathy is based on the general principles of treating nonspecific back pain. The drugs of choice for acute back pain are non-steroidal anti-inflammatory drugs, when choosing which you need to take into account their pharmacodynamics and pharmacokinetics. Artoxan (tenoxicam) according to these parameters demonstrates proper efficiency and safety. In a patient with a polyneuropathic component of back pain and diabetic polyneuropathy, it is advisable to include the drug Cocarnit in complex therapy. The quadro-effect of Cocarnit components is able to influence different points of formation of complications of diabetes and significantly improve the quality of life of such patients, restoring neurometabolic processes, reducing pain, the drug increases patient adherence to therapy.

KEYWORDS: comorbidity, pain, diabetes, diabetic dorsopathy

For citation: Rachin A.P., Sharov M.N., Rachin S.A., Prokofieva Y.S., Parsamyan R.R. Diabetic Dorsopathy: from Theory to Practice. Comorbidity Neurology. 2024; 1 (1): 93–101. https://doi.org/10.62505/3034-185x-2024-1-93-101 (In Russ.) 

*For correspondence: Mikhail N. Sharov, Dr. Sci. (Med.), Professor, Department of Nervous Diseases, Faculty of Stomatology, Russian University of Medicine, Moscow, Russia, e-mail: 6112286@mail.ru

REFERENCES

1. Silberberg R. The skeleton in diabetes mellitus: a review of the literature. Diabetes Res. 1986; 3 (7): 329–338.

2. King K.B., Rosenthal A.K. The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms. Osteoarthr Cartil. 2015; 23 (6): 841–850. https://doi.org/10.1016/j.joca.2015.03.031

3. Robinson D., Mirovsky Y., Halperin N., et al. Changes in proteoglycans of intervertebral disc in diabetic patients. A possible cause of increased back pain. Spine (Phila Pa 1976). 1998; 23 (8): 849–855.

4. Hadjipavlou A.G., Tzermiadianos M.N., Bogduk N., et al. The pathophysiology of disc degeneration: a critical review. J Bone Joint Surg Br.2008; 90 (10): 1261–1270. https://doi.org/10.1302/0301-620X.90B10.20910

5. Fabiane S.M., Ward K.J., Iatridis J.C., et al. Does type 2 diabetes mellitus promote intervertebral disc degeneration? Eur Spine J. 2016; 25 (9):2716–2720. https://doi.org/10.1016/j.spinee.2007.07.392

6. Vergroesen P.P., Kingma I., Emanuel K.S., et al. Mechanics and biology in intervertebral disc degeneration: a vicious circle. Osteoarthr Cartil.2015; 23 (7): 1057–1070. https://doi.org/10.1016/j.joca.2015.03.028

7. Antoniou J., Steffen T., Nelson F., et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Investig. 1996. 98 (4): 996–1003. https://doi.org/10.1172/JCI118884

8. Erwin W.M., De Souza L., Funabashi M., et al. The biological basis of degenerative disc disease: proteomic and biomechanical analysis of the canine intervertebral disc. Arthr Res Ther. 2015; 17: 240. https://doi.org/10.1186/s13075-015-0733-z

9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54 (6): 1615–1625.

10. Chen S., Liao M., Li J., et al. The correlation between microvessel pathological changes of the endplate and degeneration of the intervertebral disc in diabetic rats. Exp Ther Med. 2013; 5 (3): 711–717. https://doi.org/10.3892/etm.2012.868

11. Stephan S., Johnson W.E., Roberts S. The infl uence of nutrient supply and cell density on the growth and survival of intervertebral disc cells in 3D culture. Eur Cell Mater. 2011; 5 (22): 97–108.

12. Urban J.P., Smith S., Fairbank J.C. Nutrition of the intervertebral disc. Spine (Phila Pa 1976). 2004; 29 (23): 2700–2709.

13. Wang F., Cai F., Shi R., et al. Aging and age related stresses: a senescence mechanism of intervertebral disc degeneration. Osteoarthr Cartil.2016; 24 (3): 398–408. https://doi.org/10.1016/j.joca.2015.09.019

14. Won H.Y., Park J.B., Park E.Y., et al. Effect of hyperglycemia on apoptosis of notochordal cells and intervertebral disc degeneration in diabetic rats. J Neurosurg Spine. 2009; 11 (6): 741–748. https://doi.org/10.3171/2009.6.SPINE09198

15. Kong J.G., Park J.B., Lee D., et al. Effect of high glucose on stress-induced senescence of nucleus pulposus cells of adult rats. Asian Spine J. 2015; 9 (2): 155–161. https://doi.org/10.4184/asj.2015.9.2.155

16. Zhang F., Zhao X., Shen H., et al. Molecular mechanisms of cell death in intervertebral disc degeneration. Int J Mol Med. 2016; 37 (6):1439–1448. https://doi.org/10.3892/ijmm.2016.2573

17. Ding F., Shao Z.W., Xiong L.M. Cell death in intervertebral disc degeneration. Apoptosis. 2013; 18 (7): 777–785. https://doi.org/10.1007/s10495-013-0839-1

18. Zhao C.Q., Jiang L.S., Dai L.Y. Programmed cell death in intervertebral disc degeneration. Apoptosis. 2006; 11 (12): 2079–2088. https://doi.org/10.1007/s10495-006-0290-7

19. Park E.Y., Park J.B. High glucose-induced oxidative stress promotes autophagy through mitochondrial damage in rat notochordal cells. Int Orthop. 2013; 37 (12): 2507–2514. https://doi.org/10.1007/s00264-013-2037-8

20. Jiang L., Zhang X., Zheng X., et al. Apoptosis, senescence, and autophagy in rat nucleus pulposus cells: implications for diabetic intervertebral disc degeneration. J Orthop Res. 2013; 31 (5): 692–702. https://doi.org/10.1002/jor.22289

21. Park J.S., Park J.B., Park I.J., et al. Accelerated premature stress-induced senescence of young annulus fi brosus cells of rats by high glucose-induced oxidative stress. Int Orthop. 2014; 38 (6): 1311–1320. https://doi.org/10.1007/s00264-014-2296-z

22. Park Kong C.G., Park J.B., Kim M.S., et al. High glucose accelerates autophagy in adult rat intervertebral disc cells. Asian Spine J. 2014; 8 (5):543–548. https://doi.org/10.4184/asj.2014.8.5.543

23. Ye W., Xu K., Huang D., et al. Age-related increases of macroautophagy and chaperone-mediated autophagy in rat nucleus pulposus. Connect Tissue Res. 2011; 52 (6): 472–478. https://doi.org/10.3109/03008207.2011.564336

24. Caramés B., Hasegawa A., Taniguchi N., et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 2012; 71 (4): 575–581. https://doi.org/10.1136/annrheumdis-2011-200557

25. Feng C., Liu H., Yang M., et al. Disc cell senescence in intervertebral disc degeneration: causes and molecular pathways. Cell Cycle. 2016; 15 (13): 1674–1684. https://doi.org/10.1080/15384101.2016.1152433

26. Chen D., Xia D., Pan Z., et al. Metformin protects against apoptosis and senescence in nucleus pulposus cells and ameliorates disc degeneration in vivo. Cell Death Dis. 2016; 7 (10): e2441. https://doi.org/10.1038/cddis.2016.334

27. Burg M.B., Ferraris J.D., Dmitrieva N.I. Cellular response to hyperosmotic stresses. Physiol Rev. 2007; 87 (4): 1441–1474. https://doi.org/10.1152/physrev.00056.2006

28. Brocker C., Thompson D.C., Vasiliou V. The role of hyperosmotic stress in infl ammation and disease. Biomol Concepts. 2012; 3 (4): 345–364. https://doi.org/10.1515/bmc-2012-0001

29. Ishihara H., Warensjo K., Roberts S., et al. Proteoglycan synthesis in the intervertebral disk nucleus: the role of extracellular osmolality. Am J Physiol. 1997; 272 (5 Pt 1): C1499–C1506. https://doi.org/10.1152/ajpcell.1997.272.5.C1499

30. Cheng X., Ni B., Zhang Z. et al. Polyol pathway mediates enhanced degradation of extracellular matrix via p38 MAPK activation in intervertebral disc of diabetic rats. Connect Tissue Res. 2013. 54 (2):118–122. https://doi.org/10.3109/03008207.2012.754886

31. Chung S.S., Ho E.C., Lam K.S., et al. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003; 14 (8 Suppl 3): S233–S236.

32. Ziv I., Moskowitz R.W., Kraise I., et al. Physicochemical properties of the aging and diabetic sand rat intervertebral disc. J Orthop Res. 1992; 10 (2): 205–210.

33. Silberberg R. The vertebral column of diabetic sand rats (Psammomys obesus). Exp Cell Biol. 1988; 56 (4): 217–220. 

34. Aufdermaur M., Fehr K., Lesker P., et al. Quantitative histochemical changes in intervertebral discs in diabetes. Exp Cell Biol. 1980; 48 (2):89–94.

35. Aldhahi W., Hamdy O. Adipokines, infl ammation, and the endothelium in diabetes. Curr Diab Rep. 2003; 3 (4): 293–298. https://doi.org/10.1007/s11892-003-0020-2

36. Al-Hamodi Z., Al-Habori M., Al-Meeri A., et al. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr. 2014; 6 (1): 99. https://doi.org/10.1186/1758-5996-6-99

37. Segar A., Urban J., Fairbank J.C.T. Adipokines and the intervertebral disc: a biochemical link exists between obesity, intervertebral disc degeneration and low back pain. Spine J. 2016; 16: S225. https://doi.org/10.1016/j.spinee.2016.07.135

38. Инструкция по медицинскому применению препарата Артоксан, таблетки РН 006943/ https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6385877b-6e19-4027-8491-9009d2566748

39. Kashevarova N.G., Taskina E.A., Strebkova E.A., et al. A prospective comparative randomized trial of the effi cacy and safety of topical tenoxicam and diclofenac in knee osteoarthritis. Modern Rheumatology Journal. 2023; 17 (3): 51–59. https://doi.org/10.14412/1996-7012-2023-3-51-59 (In Russ.)

40. Karateev A.E., Lila A.M. Topical NSAIDs forms: effi ciency and safety. RMJ. Medical Review. 2019; 11 (II): 75–80 (In Russ.)

41. Drobyshev V.А. Effi ciency of electrophoresis and phonophoresis of artrosilene in complex treatment at dorsopathy. Medical and Pharmaceutical Sciences. 2013; 1. (In Russ.)

42. Florent Richy NSAIDS, malignancies and GI adverse events: A FAERS analysis. January 2018. https://doi org/10.15761/GMO.1000137

43. Rachin A.P., Vygov skaya S.N., Nuvakhova M.B., et al. Observational study of the effi ciency and safety of the use of tenoxicam in dorsalgy in comparison with meloxicam and diclofenac-sodium. RMJ. 2018; 4 (II). P. 43–46. (In Russ.)

44. Инструкция по применению препарата Кокарнит. http://worldmedicine.by/preparaty/metabolicheskie-i-antioksidantnye-sredstva/497-kokarnit

45. Rachin A.P., Sharov M.N. Comparative opened randomized study on assessment of effi ciency and safety of the use of Cocarnit in patients with diabetic polyneuropathy. RMJ. 2017; 9: 586–590. (In Russ.)

46. Forssell M.Z. The Back School. Spine.1981; 6: 104–106.

47. Wu P.H., Kim H.S., Jang I.T. Intervertebral Disc Diseases Part 2: A Review of the Current Diagnostic and Treatment Strategies for Intervertebral Disc Disease. Int. J. Mol. Sci. 2020; 21: 2135.

48. Alpantaki K., Kampouroglou A., Koutserimpas C., et al. Diabetes mellitus as a risk factor for intervertebral disc degeneration: a critical review. European Spine Journal. 2019; 28: 2129–2144. https://doi org/10.1007/s00586-019-06029-7.

49. Mohd Isa I.L., Teoh S.L., Mohd Nor N.H., et al. Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration. Int. J.Mol. Sci. 2023; 24: 208. https://doi.org/10.3390/ijms24010208

50. North American Spine Society. Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis & Treatment of Low Back Pain; North American Spine Society: Burr Ridge, IL, USA, 2020.

51. Mkrtumyan A.M., Oranskaya A.N. Cocarnit — Highly Effective and Safe Approach to the Treatment of Diabetic Neuropathy. Effective Pharmacotherapy. 2022; 18 (10): 10–16. https://doi org/ 10.33978/2307-3586-2022-18-10-10-16 (In Russ.)

ADDITIONAL INFORMATION
Andrei P. Rachin, Dr. Sci. (Med.), Professor, President of the National Association of Experts on Comorbid Neurology, Moscow, Russia. E-mail: 7851377@gmail.com. ORCID: https://orcid.org/0000-0003-4266-0050

Mikhail N. Sharov, Dr. Sci. (Med.), Professor, Department of Nervous Diseases, Faculty of Dentistry, Russian University of Medicine, Moscow, Russia. E-mail: 6112286@mail.ru. ORCID: https://orcid.org/0000-0001-9634-346X

Sergey A. Rachin, Executive Director, National Association of Experts on Comorbid Neurology, Moscow, Russia. E-mail: Rachin.sergei@gmail.com. ORCID: https://orcid.org/0000-0001-9771-4621

Yulia S. Prokofieva, Postgraduate Student of the Department of Nervous Diseases, Faculty of Dentistry, Russian University of Medicine, Moscow, Russia. E-mail: pryulek@yandex.ru. ORCID: https://orcid.org/0000-0003-4454-7174

Ruzanna R. Parsamyan, Cand. Sci. (Med.), Associate Professor of the Department of Neurology named after. K.N. Tretyakova, Senior Researcher at the Department of Basic Research in Neurocardiology, Research Institute of Cardiology, Saratov State Medical University, Head of Clinic Pain, Saratov, Russia. E-mail: kvl.prr@mail.ru. ORCID: https://orcid.org/0000-0002-6509-5958

Author contributions. All authors confirm the compliance of their authorship, according to international ICMJE criteria (all authors made a significant contribution to the development of the concept, research and preparation of the article, read and approved the final version before publication). Rachin S.A., Prokofieva Yu.S., Parsamyan R.R. – searched for suitable literature; Rachin A.P., Sharov M.N. – correcting the text in accordance with the basic requirements.

Funding. This study was supported by any external sources of funding.

Disclosure. The authors declare that they have competing interests.

The content is available under the Creative Commons Attribution 4.0 License.

©2024. Andrei P. Rachin, Mikhail N. Sharov, Sergei A. Rachin, Yulia S. Prokofieva, Ruzanna R. Parsamyan